Part D Subsidy End Triggers Premium Hikes and Class-Action Risk

The immediate legal fact is not simply that CMS is removing a $9.8 billion cushion after 2026. It is that the bill will not land evenly. Standalone prescription drug plan enrollees are the group most exposed to the withdrawal of the Part D Premium Stabilization Demonstration, while Medicare Advantage drug plan enrollees are largely insulated by a very different premium baseline and plan economics.

CMS’s temporary demonstration reduced the base beneficiary premium by $15 in 2025 and $10 in 2026, while also limiting annual increases under the demonstration design. KFF estimates the demonstration cost $9.8 billion across 2025 and 2026, with $6.2 billion in 2025 and $3.6 billion in 2026, and says the end of the program could mean larger premium increases for some beneficiaries next year.[1]

CMS’s public framing is narrower. In its July 28, 2026, fact sheet, the agency said Administrator Mehmet Oz stated that premiums will rise “less than $10 for most Medicare recipients.” The same release reports a 2027 national average monthly bid amount of $296.05, up from $262.86 in 2026, and a base beneficiary premium of $41.33, up from $38.99.[2] Those figures matter, but they do not answer the litigation-risk question by themselves. A class lawyer would ask which beneficiaries move from “less than $10” to something closer to $20, whether that group can be defined cleanly, and whether the government gave itself enough room to say the change was expected all along.

The Premium Increase Is Concentrated, Not Universal

The useful comparison is not every Part D enrollee against every other Part D enrollee. It is standalone PDP beneficiaries against MA-PD beneficiaries. In 2026, the average standalone PDP premium was $36 per month, more than four times the $8 average MA-PD premium. GAO reported that the demonstration subsidy accounted for $16 of the lower PDP premium, and projected that without the demonstration in 2025 premiums would have nearly doubled, with 37% of beneficiaries facing increases exceeding $40 per month.[3]

That spread is why the $9.8 billion headline is both important and easy to misuse. It identifies the size of the removed support, not the damages of any one beneficiary and not necessarily the recoverable amount for a putative class. The household-level injury is smaller, recurring, and uneven: opening the annual notice, finding a higher drug premium, deciding whether to shop plans, and then paying the new amount month after month. That is harder to dramatize than a multibillion-dollar transfer, but it is also closer to how a court would test injury.

KFF’s read of the CMS decision points to subpopulations facing increases up to $20 per month.[1] That does not make a $20 increase the experience of all Part D enrollees. It does make the “less than $10 for most” formulation incomplete for legal screening, because “most” can be true while a narrower group remains identifiable, injured, and worth pleading around.

Why Standalone PDP Enrollees Are the Natural Starting Class

Standalone PDP enrollees have the cleanest factual story because the demonstration was aimed at stabilizing their premiums after the redesign of Part D. They also lack the same built-in shelter that many MA-PD enrollees receive through Medicare Advantage plan pricing. For a complaint drafter, that creates a more administrable starting point than “all Medicare beneficiaries affected by CMS’s decision.”

The class still narrows quickly. Low-income subsidy beneficiaries receiving Extra Help are separately protected, which reduces the group directly affected by the end of the demonstration. The Inflation Reduction Act’s statutory 6% cap on increases in the base beneficiary premium remains in place through 2029, which gives CMS a ready answer to claims that the withdrawal leaves beneficiaries without any premium protection.[2]

That cap does not erase plan-level premium increases. It does, however, complicate any theory that treats the end of the demonstration as a catastrophic loss of statutory stability. The better factual theory is narrower: CMS withdrew a temporary layer of support that had a larger practical value for standalone PDP enrollees than for MA-PD enrollees, and the timing and distribution of that withdrawal created a predictable premium shock for a defined subgroup.

Reliance Is the Strongest Pre-Litigation Theory

The most concrete legal theory is not a generalized unfairness claim. It is an Administrative Procedure Act challenge built around reliance interests and agency timing. CMS had described the demonstration as lasting “at least three years,” and participation was broad: 782 of 818 PDPs opted in, covering 99% of enrollees.[1] Plan sponsors then submitted 2027 bids by June 1, 2026, before CMS announced on July 28, 2026, that the subsidy would end after 2026.[2]

That sequence is the kind of fact pattern lawyers notice. The plans had to price before the termination announcement. Beneficiaries had no practical reason to understand the mechanics of a federal demonstration that was reducing premiums in the background. If notices later show higher standalone PDP premiums, a plaintiff could argue that CMS failed to adequately account for reliance by plans and enrollees before removing the support.

The weakness is just as visible. CMS can point to the demonstration’s own step-down: $15 in 2025, $10 in 2026, and then no subsidy in 2027.[1] A court reviewing arbitrary-and-capricious claims will not necessarily treat that sequence as a sudden reversal. The agency can argue that it deliberately tapered an emergency stabilization measure as insurers gained experience with the redesigned Part D benefit, and that the IRA’s separate premium cap remained in place.

Standing also becomes messy. Plans have the bid-timing facts, but beneficiaries pay the premium. Beneficiaries have the pocketbook injury, but not necessarily the same direct reliance on CMS’s communications. A well-built case would need to bridge that gap without turning plan-side disappointment into beneficiary damages by assumption.

Disparate Impact Helps Identify the Burden, but It Does Not Carry the Case Alone

The PDP-versus-MA-PD split is useful because it shows the burden is patterned. Standalone PDP beneficiaries entered 2026 with a much higher average premium than MA-PD beneficiaries, and the demonstration’s premium support mattered more to that standalone market.[3] If premium notices in the fall of 2026 show a visible cluster of increases near the upper end identified by KFF, the factual map becomes easier to draw.[1]

But disparate impact is not the same thing as a cause of action. A comparison between PDP and MA-PD enrollees may support a narrative of unequal burden, yet it does not automatically supply a protected class, a statutory right to identical treatment, or a damages theory. The Medicare program routinely produces different premium outcomes across plan types. A plaintiff would need more than a chart showing that one market absorbed more of the subsidy withdrawal.

The more disciplined use of disparate-impact evidence is as a targeting device. It can help define the affected population, test whether named plaintiffs are typical, and show why CMS’s “most recipients” framing may obscure the subgroup that matters. It is weaker as a standalone merits theory unless tied to a specific statutory or constitutional hook.

Medicare Act and Equal-Protection Theories Face a Narrow Road

A Medicare Act theory would likely focus on whether CMS’s use and termination of the demonstration interacts improperly with premium-stabilization provisions for Part D. The problem is that the statutory 6% cap on the base beneficiary premium remains active through 2029.[2] That makes it difficult to argue that CMS abandoned premium stabilization altogether. The more plausible argument would be technical: that the agency failed to justify how ending the demonstration fit with the statutory stabilization framework after inducing market-wide reliance.

Even that version faces review-channel problems. Medicare disputes often move through specialized statutory pathways before general federal-court review is available. A beneficiary-side case would need to establish that the challenged agency action is reviewable in the chosen forum, that the named plaintiffs have suffered a concrete premium injury, and that the requested relief would redress that injury rather than simply reopen a completed bid cycle.

Equal-protection framing is thinner. Unless plaintiffs can connect the PDP burden to a protected classification or show irrational treatment under the applicable standard, the government has an obvious response: PDP and MA-PD products are not priced the same way, the demonstration was temporary, and CMS phased it down before ending it. Unequal economic effects alone rarely do the work that a constitutional claim needs.

The Bid Calendar Is More Important Than the Politics

For litigation risk, the key timing point is not the partisan argument over whether the demonstration was too expensive. It is the June 1 bid deadline followed by the July 28 termination announcement.[2] That sequence creates a concrete administrative record question: what did CMS know about likely premium effects, what assumptions did plans use when they submitted bids, and how did the agency account for beneficiaries who would receive plan-year notices after the decision was already baked into the 2027 market?

Plan sponsors may be the better source of reliance evidence, but they are not the easiest plaintiffs for a beneficiary-premium case. Beneficiaries may be better plaintiffs for injury, but their reliance story is less direct. That mismatch does not defeat litigation risk. It does mean a viable case would have to be pleaded with care, probably using the plan-side record to explain foreseeability while keeping the beneficiary injury at the center.

Readers focused on sponsor-side obligations may want the companion risk analysis of Legal Analysis of the 2027 Medicare Part D Premium Increase. The beneficiary-side class-action question turns on a different emphasis: not whether sponsors complied with the bid process, but whether the end of the subsidy left a definable group paying more after an agency course change that was insufficiently explained.

No Identified Complaint Yet, and the Class Would Not Be as Broad as the Headline

As of late July 2026, no lawsuit challenging either the demonstration’s legality or its termination has been identified. That matters. The present risk is prospective: a factual pattern is forming, but it has not yet been tested through named plaintiffs, venue choices, exhaustion arguments, class-certification theories, or a developed administrative record.

The strongest hypothetical class would not be all Medicare beneficiaries, or even all Part D enrollees. It would likely begin with standalone PDP enrollees who are not separately protected by Extra Help, who experience a premium increase traceable to the end of the demonstration, and who can show the increase is not merely the result of unrelated plan design, formulary, or regional pricing changes. That is a narrower and more legally useful class than the aggregate $9.8 billion figure suggests.

The subsidy end creates a plausible factual map for beneficiary-side challenges because the burden falls unevenly on standalone PDP enrollees. The same record also gives CMS several defenses: the demonstration was scaled down before it ended, the IRA’s 6% cap still limits the base beneficiary premium, Extra Help beneficiaries remain separately protected, and Medicare review channels can make even a well-framed premium challenge hard to get into court.

References

1. CMS’s Decision To End Temporary Subsidies to Medicare’s Stand-Alone Drug Plans Could Mean Larger Premium Increases for Some Beneficiaries Next Year, KFF, July 29, 2026.
2. Medicare Part D 2027 National Average Monthly Bid Amount Information, Centers for Medicare & Medicaid Services, July 28, 2026.
3. GAO-26-107935, U.S. Government Accountability Office, February 2026.